@article{89ee63b5c6a24f60bd7c495996bb9aa4,
title = "COVID-19 in the pregnant or postpartum MS patient: Symptoms and outcomes",
abstract = "Women with multiple sclerosis (MS) are often of childbearing age. Thirty-six women with MS who were pregnant (n = 27) or within 6 weeks postpartum (n = 9) were reported in the North American COViMS registry and their COVID-19 outcomes were described. One pregnant and one postpartum woman were hospitalized. No deaths occurred. To compare COVID-19 clinical outcomes in pregnant and postpartum females with females who were not pregnant or postpartum, a 1:2 propensity score match was performed. While not powered to detect small differences, it was reassuring that no increased risks for those with MS who were pregnant/postpartum were revealed.",
keywords = "COVID-19, Multiple sclerosis, Postpartum, Pregnancy, SARS-CoV-2",
author = "Amber Salter and Cross, {Anne H.} and Cutter, {Gary R.} and Fox, {Robert J.} and Li, {David K.B.} and Bruce Bebo and June Halper and Pamela Kanellis and Kottil Rammohan and Newsome, {Scott D.}",
note = "Funding Information: Dr Salter reports honoraria for consulting for Gryphon Bio, LLC and research funding from Multiple Sclerosis Society of Canada, National Multiple Sclerosis Society, CMSC and the US Department of Defense. She is a member of the Editorial Board for Neurology. Dr. Salter is a member of the Data and Safety Monitoring Board for Premature Infants Receiving Milking or Delayed Cord Clamping (PREMOD2), Central Vein Sign: A Diagnostic Biomarker in Multiple Sclerosis (CAVS-MS), and Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease (CELLO). Funding Information: Dr Fox reports personal fees from AB Science, Biogen, Celgene, EMD Serono, Genentech, Genzyme, Greenwich Biosciences, Immunic, Janssen, Novartis, Sanofi, and TG Therapeutics. Dr. Fox has served on advisory committees for AB Science, Biogen, Genzyme, Immunic, Janssen, Novartis, Sanofi, and TG Therapeutics, and received clinical trial contract and research grant funding from Biogen, Novartis, and Sanofi. Funding Information: Dr Rammohan reports honoraria from Alexion, Sanofi Genzyme, Genentech, Novartis, EMD Serono, Biogen, Horizon and grants from Alexion, Sanofi Genzyme, Genentech, Novartis, Biogen. Funding Information: Dr Li reports personal fees from Biogen and personal fees from Sanofi Genzyme; grants from Sanofi Genzyme, Roche, Novartis, and MS Society of Canada; is emeritus director of the University of British Columbia Multiple Sclerosis/ Magnetic Resonance Imaging Research Group, which has been contracted to perform central analysis of magnetic resonance imaging scans for therapeutic trials with Roche and SanofiGenzyme and has received grant support for investigator-initiated studies from Sanofi Genzyme, Novartis, and Roche; and has served on the Progressive Multifocal Leukoencephalopathy– Multiple Sclerosis Steering Committee for Biogen and given lectures, supported by nonrestricted education grants from Academy of Healthcare Learning, Biogen, Consortium of Multiple Sclerosis Centers, and Sanofi Genzyme outside the submitted work. Publisher Copyright: {\textcopyright} 2022 Elsevier B.V.",
year = "2022",
month = sep,
doi = "10.1016/j.msard.2022.104028",
language = "English (US)",
volume = "65",
journal = "Multiple Sclerosis and Related Disorders",
issn = "2211-0348",
publisher = "Elsevier",
}